Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b
Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b
复制标题
DOI：
10.1385/bter:75:1-3:53
复制
发表时间：
2000-06-01
影响因子：
3.9
通讯作者：
Nakajima, K
中科院分区：
文献类型：
--
作者：
Nagamine, T;Takagi, H;Nakajima, K
我们已经评估了干扰素-α（IFN-α）加锌治疗对基因型1b的丙型肝炎患者的疗效，单独使用IFN的反应较差。对照组10例，每天注射IFN-α 10 MU，共4 wk，然后每周注射3次，共20 wk。9例患者在IFN-α治疗期间每天口服硫酸锌300 mg（硫酸锌组），15例患者在IFN-α治疗期间每天口服Polaprezinc 150 mg（Polaprezinc组）。在IFN治疗结束后6个月，Polaprezinc组73.3%、硫酸锌组55.6%和对照组40.0%的血清ALT水平恢复正常。在6个月随访期结束时，Polaprezinc组判定的丙型肝炎病毒RNA持续根除率高于硫酸锌组（53.3% vs 11.1%，p < 0.05）或对照组（20.0%）。在所用剂量下未观察到锌的临床副作用。这些数据表明，Polaprezinc有望增加IFN-α对基因型1b的慢性丙型肝炎的治疗反应。
We have evaluated the efficacy of interferon-alpha (IFN-alpha) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-alpha every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-alpha therapy (zinc sulfate group), and 15 patients took IFN-alpha and 150 mg of polaprezinc (polaprezinc group).On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p < 0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-alpha for chronic hepatitis C with genotype 1b.